Full Text View
Tabular View
No Study Results Posted
Related Studies
Topical Imiquimod in Treating Patients With Recurrent Paget's Disease of the Vulva
This study is currently recruiting participants.
Verified by National Cancer Institute (NCI), July 2009
First Received: July 17, 2007   Last Updated: July 7, 2009   History of Changes
Sponsors and Collaborators: Memorial Sloan-Kettering Cancer Center
National Cancer Institute (NCI)
Information provided by: National Cancer Institute (NCI)
ClinicalTrials.gov Identifier: NCT00504023
  Purpose

RATIONALE: Biological therapies, such as imiquimod, may stimulate the immune system in different ways and stop tumor cells from growing. Applying topical imiquimod to the vulva may be an effective treatment for recurrent Paget's disease.

PURPOSE: This clinical trial is studying how well topical imiquimod works in treating patients with recurrent Paget's disease of the vulva.


Condition Intervention
Vulvar Cancer
Drug: imiquimod
Procedure: biopsy
Procedure: conventional surgery

Study Type: Interventional
Study Design: Treatment
Official Title: A Pilot Study of Topical Imiquimod Therapy for the Treatment of Recurrent Extramammary Paget's Disease

Resource links provided by NLM:


Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Clinical and histologic effects [ Designated as safety issue: No ]

Estimated Enrollment: 20
Study Start Date: April 2007
Estimated Primary Completion Date: April 2010 (Final data collection date for primary outcome measure)
Detailed Description:

OBJECTIVES:

  • To assess the clinical and histologic effects of topical imiquimod therapy on recurrent extramammary Paget's disease.

OUTLINE: This is a pilot, prospective, multicenter study.

Patients apply topical imiquimod cream to a target vulvar lesion 3 times weekly. Treatment continues for up to 12 weeks in the absence of disease progression or unacceptable toxicity. If the lesion is still present after completion of 12 weeks of imiquimod therapy, the patient undergoes surgical excision of the target lesion (and any other progressive lesions suspicious for evolving adenocarcinoma) at week 16.

Patients undergo punch biopsy and photographic assessment of a target vulvar lesion at baseline and again at 12 weeks.

After completion of imiquimod therapy or after surgical excision, patients are followed at 6 weeks and then every 3 months for at least 2 years.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

DISEASE CHARACTERISTICS:

  • Patients who present to the Gynecology outpatient clinic of Memorial Sloan-Kettering Cancer Center (MSKCC) meeting the following criteria:

    • Biopsy-proven extramammary Paget's disease of the vulva with histological confirmation performed at MSKCC

      • No underlying adenocarcinoma on biopsy of lesion
  • Recurrent disease

PATIENT CHARACTERISTICS:

  • No known hypersensitivity to imiquimod
  • Not pregnant or nursing

PRIOR CONCURRENT THERAPY:

  • Not specified
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00504023

Locations
United States, Louisiana
Feist-Weiller Cancer Center at Louisiana State University Health Sciences Recruiting
Shreveport, Louisiana, United States, 71130-3932
Contact: Clinical Trials Office - Feist-Weiller Cancer Center at Louisi     318-813-1412        
United States, New York
Memorial Sloan-Kettering Cancer Center Recruiting
New York, New York, United States, 10065
Contact: Dennis S. Chi, MD, FACOG, FACS     212-639-5016        
Sponsors and Collaborators
Memorial Sloan-Kettering Cancer Center
Investigators
Principal Investigator: Dennis S. Chi, MD, FACOG, FACS Memorial Sloan-Kettering Cancer Center
Principal Investigator: Robert Soslow, MD Memorial Sloan-Kettering Cancer Center
  More Information

Additional Information:
No publications provided

Study ID Numbers: CDR0000556722, MSKCC-07029
Study First Received: July 17, 2007
Last Updated: July 7, 2009
ClinicalTrials.gov Identifier: NCT00504023     History of Changes
Health Authority: Unspecified

Keywords provided by National Cancer Institute (NCI):
Paget disease of the vulva
recurrent vulvar cancer
stage 0 vulvar cancer
stage I vulvar cancer
stage II vulvar cancer
stage III vulvar cancer

Study placed in the following topic categories:
Immunologic Factors
Interferons
Vulvar Cancer
Adjuvants, Immunologic
Genital Neoplasms, Female
Imiquimod
Urogenital Neoplasms
Bone Diseases
Recurrence
Paget's Disease, Extramammary
Carcinoma
Genital Diseases, Female
Musculoskeletal Diseases
Vulvar Neoplasms
Osteitis Deformans
Paget Disease
Adenocarcinoma
Osteitis
Vulvar Diseases
Neoplasms, Glandular and Epithelial

Additional relevant MeSH terms:
Interferon Inducers
Neoplasms by Histologic Type
Immunologic Factors
Antineoplastic Agents
Physiological Effects of Drugs
Adjuvants, Immunologic
Genital Neoplasms, Female
Imiquimod
Urogenital Neoplasms
Bone Diseases
Pharmacologic Actions
Paget's Disease, Extramammary
Carcinoma
Genital Diseases, Female
Neoplasms
Neoplasms by Site
Musculoskeletal Diseases
Vulvar Neoplasms
Therapeutic Uses
Osteitis Deformans
Neoplasms, Ductal, Lobular, and Medullary
Adenocarcinoma
Vulvar Diseases
Neoplasms, Glandular and Epithelial

ClinicalTrials.gov processed this record on September 11, 2009